By admin 
The announcement by Defense Secretary Pete Hegseth that the Department of Defense (DOD) will implement a mandatory testosterone screening program for all U.S. service members aged 30 and older marks a radical departure from traditional military medical readiness protocols. This directive, which aims to monitor and potentially intervene in the hormonal health of hundreds of thousands of active-duty personnel, has sparked intense debate among urologists, endocrinologists, and public health experts. While the initiative is framed as a move toward optimizing the physical and mental performance of the fighting force, the medical community warns that population-level screening of asymptomatic individuals is a "novel experiment" that lacks a foundation in established clinical guidelines. As a practicing urologist and health outcomes researcher who has spent years studying men’s health and the impacts of large-scale screening within the military health system, I believe it is essential to look beyond the surface-level promise of "hormonal optimization" and examine the complex physiological, logistical, and ethical ramifications of this policy.
Testosterone is the primary male sex hormone, but its role in the body is far more nuanced than its popular association with muscle mass and aggression suggests. It is the product of a delicate and highly regulated feedback loop known as the hypothalamic-pituitary-gonadal (HPG) axis. In this system, the hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the pituitary gland to produce luteinizing hormone (LH), which in turn stimulates the testes to produce testosterone. This axis is responsible for male reproductive development in utero, the physiological transformations of puberty, and the maintenance of bone density, red blood cell production, and libido throughout adulthood. However, this system is incredibly sensitive to external and internal stressors. Obesity, chronic sleep deprivation, high levels of cortisol (the stress hormone), and even certain dietary patterns can suppress the HPG axis, leading to lower-than-average testosterone readings that may not necessarily reflect a permanent medical deficiency.
The medical community has long recognized that testosterone levels naturally decline as men age, typically by about 1% to 2% per year after the age of 30. This phenomenon, sometimes colloquially referred to as "andropause," is distinct from clinical hypogonadism, which is a pathological failure of the testes or the pituitary gland. The challenge for clinicians lies in the fact that many symptoms of natural aging—such as increased body fat, decreased energy, and changes in mood—overlap with the symptoms of clinical testosterone deficiency. Because of this overlap, the American Urological Association (AUA) and the Endocrine Society have traditionally recommended against routine screening for men who do not exhibit clear, symptomatic evidence of a disorder. The DOD’s move to screen all service members over 30, regardless of whether they feel "fine," directly contradicts these long-standing medical standards.
The cultural backdrop of this policy is equally significant. We are currently witnessing an unprecedented "testosterone gold rush." The global market for testosterone replacement therapy (TRT) has undergone a staggering transformation, ballooning from roughly $18 million in annual sales in the late 1980s to an estimated $2 billion by 2025. This growth is not merely a reflection of better diagnosis; it is driven by a massive direct-to-consumer marketing machine, the proliferation of "men’s health" clinics, and a digital landscape where influencers equate high testosterone with leadership, virility, and success. In many cases, these commercial entities bypass traditional urological expertise, offering online prescriptions through loosely regulated platforms. As a result, many men are now entering doctors’ offices with "supraphysiological" levels—testosterone concentrations far exceeding what is naturally safe—increasing their risk for serious side effects.
While TRT can offer significant benefits for men with legitimate clinical hypogonadism, including improved muscle mass, bone density, and sexual function, the risks of widespread supplementation among relatively healthy younger men cannot be ignored. Historically, the safety profile of testosterone has been a subject of intense scrutiny. In 2010, a landmark study known as the TOM (Testosterone in Older Men with Mobility Limitations) trial was abruptly halted by its safety monitoring board. The researchers found that men in the testosterone group experienced a significantly higher rate of major adverse cardiovascular events, including heart attacks and strokes, compared to those in the placebo group. While this study focused on older men with pre-existing mobility issues, it served as a cautionary tale about the systemic effects of hormonal manipulation.
More recently, the 2023 TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) trial provided a more nuanced view. This large-scale, randomized controlled trial found that TRT did not increase the risk of major cardiac events compared to a placebo over a multi-year period. However, the TRAVERSE trial was not a "clean bill of health." It revealed a higher incidence of other serious conditions among those taking testosterone, including acute kidney injury, atrial fibrillation (a heart rhythm disorder that increases stroke risk), and pulmonary embolism (life-threatening blood clots in the lungs). For a military population that must be ready for high-intensity physical exertion in extreme environments, these risks are particularly concerning.
My own research, which focused specifically on the military’s health insurance system (TRICARE), has uncovered further complications. In studies supported by the DOD, my colleagues and I analyzed health outcomes for thousands of service members and their beneficiaries who used testosterone supplementation. Our data indicated a statistically significant increase in the rate of kidney stones among TRT users. Perhaps more critically for active-duty personnel, we also found a higher incidence of obstructive sleep apnea—a condition that can severely impair cognitive function and physical endurance. While some of our findings suggested improvements in certain cardiovascular markers, the overall picture is one of a "trade-off" rather than a simple upgrade in health.
The decision to start screening at age 30 is especially noteworthy because of the impact on fertility. Testosterone supplementation works through a negative feedback loop: when the body detects high levels of exogenous (external) testosterone, the pituitary gland stops sending signals to the testes to produce its own hormone. This effectively shuts down natural sperm production. For men in their 30s and 40s who may be planning to start or expand their families, TRT can lead to profound infertility and testicular atrophy (shrinkage). Both the AUA and the Endocrine Society explicitly warn against the use of testosterone in men who desire future fertility. If the DOD proceeds with this screening, it must ensure that every service member who tests "low" is fully informed that the "cure" for their low energy might prevent them from ever having children.
Logistically, the implementation of a mandatory screening program across the entire Department of Defense is a Herculean task. Accurate testosterone testing is notoriously difficult. Levels fluctuate significantly throughout the day, peaking in the early morning. To get a valid reading, blood must be drawn between 7:00 AM and 10:00 AM, ideally while the patient is fasting. Clinical guidelines require at least two separate tests on different days to confirm a diagnosis of low testosterone, as a single low reading is often a temporary anomaly. Furthermore, a low total testosterone level should always be followed by tests for free testosterone, luteinizing hormone, and prolactin to determine the underlying cause. If the DOD simply relies on a single "mandatory" blood draw during a routine physical, it risks a massive wave of false-positive diagnoses, leading to unnecessary and potentially harmful treatment.
Furthermore, once a service member begins TRT, they require lifelong monitoring. This includes regular blood work to check hematocrit levels—the percentage of red blood cells in the blood. Testosterone stimulates the production of red blood cells; if these levels get too high (a condition called erythrocytosis), the blood becomes viscous, significantly increasing the risk of blood clots and strokes. In a military health system already strained by the demands of combat readiness and veteran care, the administrative and clinical burden of monitoring hundreds of thousands of men on hormone therapy could be overwhelming.
Secretary Hegseth has stated that while screening is mandatory, the decision to take supplements will remain voluntary for individual service members. However, in the high-pressure environment of the military, the line between "voluntary" and "expected" can become blurred. If a service member is told their testosterone is "sub-optimal" for their age, they may feel a professional obligation to "fix" the issue to remain competitive for promotions or elite assignments. This creates an ethical dilemma: are we treating a medical condition, or are we encouraging the use of performance-enhancing drugs under the guise of healthcare?
The U.S. military has a long history of leading the way in medical innovation, from trauma care to infectious disease control. However, those successes were built on rigorous evidence and a "first, do no harm" philosophy. Widespread population-level screening for a hormone as complex as testosterone, in a population that is generally younger and healthier than the average clinical patient, is a step into the unknown. Without a clear protocol for confirmatory testing, individualized counseling on fertility, and long-term monitoring for cardiovascular and renal side effects, this initiative could inadvertently undermine the very readiness it seeks to enhance. For the health and wellness of those who serve, it is imperative that this program be treated not as a simple administrative requirement, but as a high-stakes medical intervention that requires the highest level of clinical oversight and scientific humility.
